SR2067 reveals a unique kinetic and structural signature for PPARγ partial agonism
Journal Article
·
· ACS Chemical Biology
- The Univ. of Adelaide, Adelaide, SA (Australia); Office of Scientific and Technical Information (OSTI)
- The Univ. of Adelaide, Adelaide, SA (Australia)
- GE Healthcare Life Sciences ANZ, Melbourne, VIC (Australia)
- The Scripps Research Inst., Jupiter, FL (United States)
Here, synthetic full agonists of PPARγ have been prescribed for the treatment of diabetes due to their ability to regulate glucose homeostasis and insulin sensitization. While the use of full agonists of PPARγ has been hampered due to severe side effects, partial agonists have shown promise due to their decreased incidence of such side effects in preclinical models. No kinetic information has been forthcoming in regard to the mechanism of full versus partial agonism of PPARγ to date. In this paper, we describe the discovery of a partial agonist, SR2067. A co-crystal structure obtained at 2.2 Å resolution demonstrates that interactions with the β-sheet are driven exclusively via hydrophobic interactions mediated through a naphthalene group, an observation that is unique from other partial agonists. Finally, surface plasmon resonance revealed that SR2067 binds to the receptor with higher affinity (KD = 513 nM) as compared to that of full agonist rosiglitazone, yet it has a much slower off rate compared to that of rosiglitazone.
- Research Organization:
- Scripps Research Inst., Jupiter, FL (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22); USDOE Office of Science (SC), Biological and Environmental Research (BER) (SC-23)
- Grant/Contract Number:
- AC02-76SF00515
- OSTI ID:
- 1345039
- Journal Information:
- ACS Chemical Biology, Journal Name: ACS Chemical Biology Journal Issue: 1 Vol. 11; ISSN 1554-8929
- Publisher:
- American Chemical Society (ACS)Copyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes
A novel natural Nrf2 activator with PPARγ-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia
GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain
Journal Article
·
Fri Aug 28 00:00:00 EDT 2015
· Biochemical and Biophysical Research Communications
·
OSTI ID:22462221
A novel natural Nrf2 activator with PPARγ-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia
Journal Article
·
Fri Nov 01 00:00:00 EDT 2013
· Toxicology and Applied Pharmacology
·
OSTI ID:22285475
GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain
Journal Article
·
Sun May 13 20:00:00 EDT 2012
· Journal of Biological Chemistry
·
OSTI ID:1625076